Chronic obstructive pulmonary disease (COPD) remains a substantial contributor to morbidity and mortality in the United States with an estimated 3.8% age-adjusted prevalence and 141,733 COPD deaths ...

David Mannino is co-founder and chief medical officer of the COPD Foundation. He's an internal medicine doctor with a specialty in pulmonary, critical care, and sleep medicine at University of ...

Verona Pharma's ensifentrine is a first-in-class, inhaled, dual inhibitor of the enzymes PDE3 and PDE4, targeting both bronchodilation and inflammation. Positive Phase 3 results from the ENHANCE ...

At the ERS 2025 Congress, the world’s largest annual meeting on respiratory diseases, attended by international experts, one of the hot topics in pulmonary medicine was discussed this year—the ...